AGM/EGMApr 26, 2026, 05:30 AM
SVRA Annual Meeting June 4; Proposes Share Increase, Plan Amendment
AI Summary
Savara Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 4, 2026. Key proposals include the election of six directors, an amendment to increase authorized common stock from 300 million to 600 million shares, and an increase of 18.9 million shares for the 2024 Omnibus Incentive Plan. The company also provided an update on its investigational therapy, MOLBREEVI, with a US FDA Action Date of November 22, 2026, and EU/UK decisions expected in Q1 2027 and Q4 2026, respectively. Savara has strengthened its financial position with a $149.5 million equity financing and a $75 million royalty funding agreement.
Key Highlights
- Savara Inc. 2026 Annual Meeting of Stockholders to be held virtually on June 4, 2026.
- Proposes to increase authorized common stock from 300,000,000 to 600,000,000 shares.
- Proposes to increase shares for the 2024 Omnibus Incentive Plan by 18,900,000.
- MOLBREEVI US FDA Action Date set for November 22, 2026, under Priority Review.
- MOLBREEVI EU decision expected in Q1 2027 and UK decision in Q4 2026.
- Completed $149.5 million equity financing to support potential commercial launch.
- Entered into a $75 million royalty funding agreement with RTW.
- Amended debt facility to provide up to $75 million in additional debt funding upon FDA approval.